Skip to main content

Table 1 The relationship between frequency of HPV16 E6 or E7-specific T cell response in peripheral blood and clinical features in CSCC patients

From: HPV16 E6-specific T cell response and HLA-A alleles are related to the prognosis of patients with cervical cancer

Factor N E6-peptide specific T cell response E7-peptide specific T cell response
Frequency (%) P-value Frequency (%) P-value
Age (years)
 ≤ 55 38 52.63 0.105 31.58 0.807
 > 55 38 34.21   34.21  
Stage
 IIb 45 37.78 0.232 35.56 0.552
 IIIa-b 31 51.61   29.03  
Tumor size (cm)
 < 5 40 37.50 0.272 35.00 0.681
 ≥ 5 36 50.00   30.56  
Tumor type
 Cauliflower 33 45.45 0.859 27.27 0.338
 Hollow 6 33.33   16.67  
 Nodular 37 43.24   40.54  
Histologic grade
 Poor 18 38.89 0.310 27.78 0.163
 Moderate 46 45.65   34.78  
 Well 2 100   100  
 Papillary 10 33   20.00  
HPV 16
 Negative 14 50.00 0.582 42.86 0.380
 Positive 62 41.93   30.64  
TSGF
 Normal 45 44.45 0.828 37.78 0.275
 Abnormal 31 41.94   25.81  
CEA
 Normal 59 42.37 0.731 33.90 0.729
 Abnormal 17 47.06   29.41  
SCC
 Normal 20 50.00 0.489 30.00 0.748
 Abnormal 56 41.07   33.93  
Pelvic lymph nodes
 Negative 37 56.76 0.022 40.54 0.167
 Positive 39 30.77   25.64  
  1. HPV, human papillomavirus; TSGF, tumour-specific growth factor; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma antigen